Clinical trial
The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast…
NCT00097344 · Intarcia Therapeutics, Industry · Terminated
Key facts
| NCT number | NCT00097344 |
|---|---|
| Title | The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer |
| Official title | Phase 3 Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer |
| Lead sponsor | Intarcia Therapeutics, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Neoplasms, Neoplasms, Hormone-Dependent |
| Intervention type | Drug, Procedure |
| Interventions | Atamestane, Toremifene, Letrozole, Aromatase inhibition, Estrogen receptor blocker, Hormone therapy, Endocrine therapy, Antiestrogen therapy |
| Enrollment | 842 |
| Start date | Dec 1, 2004 |
| Completion | Aug 1, 2006 |
| First posted | Nov 23, 2004 |
| Last update posted | Aug 23, 2007 |
| Countries | Bulgaria, Romania, Russia, Ukraine, United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: